Remission of feline gastrointestinal eosinophilic sclerosing fibroplasia in a cat treated with corticotherapy
Loading...
Download
Official URL
Full text at PDC
Publication date
2021
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Univ. Agriculture, Fac. Veterinary Science
Citation
Agulla B, Díaz-Regañón D, García-Sancho M, Rodríguez-Franco F, Villaescusa A, Rodríguez Bertos A, Pérez Díaz C and Sainz A, 2021. Remission of feline gastrointestinal eosinophilic sclerosing fibroplasia in a cat treated with corticotherapy. Pak Vet J, 41(2): 309-312. http://dx.doi.org/10.29261/pakvetj/2021.022
Abstract
Feline Gastrointestinal Eosinophilic Sclerosing Fibroplasia (FGESF) is a rare clinical entity of unknown aetiology. The most defended hypothesis refers to a genetic alteration in the immune response regulation, which results in an exacerbated eosinophilic inflammation. The proposed treatment for FGESF includes immunosuppressive drugs and surgical resection of the lesion. A 2- and- a- half-year old neutered, male, Chartreux cat was diagnosed with FGESF with the presence of a mass in the first duodenal flexure, which was surgically removed and recurred 8 months post-surgery. After using an immunosuppressive treatment for one year, the macroscopic disappearance of the lesion and the complete remission of the clinical signs were achieved. To our knowledge, this is the first description of disappearance of a FGESF lesion located in the gastrointestinal tract after prolonged immunosuppressive treatment. This clinical report highlights the possibility to treat this new feline disease with the exclusive use of immunosuppressive drugs.
Description
Authors contribution: BA and DDR collected the cat´s follow-up and wrote the manuscript. AV wrote the manuscript. MGS, FRF and AS carried out the diagnosis, instituted the treatment and carried out the clinical followup. CPD performed the surgery. ARB carried out the histopathological diagnosis. All authors critically revised the manuscript for important intellectual contents and approved the final version.